LENALIDOMIDE DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
The patent expiry of branded drugs is posing significant challenges for the growth of the lenalidomide drug market. Lenalidomide, which is a drug used mainly in the treatment of multiple myeloma and mantle cell lymphoma, has faced increasing competition from generic drug manufacturers after its patent expired in the U.S. in 2022.
Market Opportunities – Exploring Combination Drug Therapies:
Exploring combination therapies and testing lenalidomide in other hematological cancers could significantly expand the eligible patient pool. Pursuing pediatric indications may also unlock new growth. Extending or strengthening patents could help stave off generics. Developing new formulations or delivery methods may enhance safety and patient adherence, helping maintain competitive edge even post-patent expiry.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
